Showing papers by "Tadanori Mammoto published in 1999"

Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility.

Abstract: Metastasis of cancer cells is initiated by the cellular migration into extracellular matrix and surrounding vessels. We previously showed that elevation of cAMP levels in cancer cells suppressed trans-cellular migration in vitro. Drugs that can elevate cAMP levels in cancer cells effectively may be applied to prevent metastasis in cancer patients. Cilostazol, an oral anti-platelet drug, is a specific cAMP phosphodiesterase type III inhibitor and has been clinically used to treat thrombosis patients. In chemotaxis assay, cellular migration of human colon cancer cells, DLD-1, was induced by 10 μg/ml of soluble fibronectin or 10% of fetal bovine serum (FBS). Treatment with cilostazol (50 μM) suppressed 92.3% or 84.6% of the migration in control cells, respectively. When DLD-1 cells were stimulated by soluble fibronectin in phagokinetic assay, migration assessed by the area of gold particle phagocytosis track was induced and cilostazol also decreased 67.3% of the cellular migration in control cells. Furthermore, in the trans-cellular migration assay, cilostazol suppressed cancer cell invasion induced by FBS. Thus, cilostazol can suppress colon cancer cell motility and might be effective as an anti-metastasis drug for cancer patients.

Oral clonidine reduces the requirement of prostaglandin El for induced hypotension

Abstract: To determine the effects of preanesthetic oral clonidine on the dose of prostaglandin E1 (PGE1) required to produce hypotension during anesthesia. Oral placebo, 75 μg or 150 μg clonidine were administered 60 min prior to induction of anesthesia. Anesthesia was maintained with O2: N2O (30:70) and isoflurane 1.0 %. After hemodynamic stabilization, an infusion of prostaglandin E1 was started (0.05 μg · kg−1· min−1) and the rate of infusion was adjusted to maintain mean arterial pressure (MAP) between 60–70 mmHg during operation. Duration of hypotension in placebo, 75 μg and 150μg preanesthetic oral clonidine treated groups were 132 ± 46, 117 ± 37 and 129 ± 56 min, respectively. The PGE 1 requirement in each group were 1563 ± 180 (28.6 ± 3.2), 594 ± 197 (10.8 ± 3.6) and 283 ± 30 (5.5 ± 3.6) μg (μg · kg−1), respectively. In addition, blood loss in each group were 1461 ± 389, 805 ± 240 and 931 ± 40 ml, respectively. Preanesthetic oral clonidine decreased the dose of PGE 1 required to produce hypotension, and decreased the blood loss during operation.